The Early Phase Trials team have decided to suspend recruitment of patients as a result of the evolving situation with COVID-19. We feel that this is appropriate and takes into consideration multiple factors such as the risk to patients associated with increased travelling, additional hospital visits to Addenbrooke's and concerns about the uncertainty of possible side effects associated with experimental therapy (such as myelo- and immuno-suppression or pneumonitis).
(Last updated 20/07/2020)
| Trial Short Name | Molecular Target(s) | Patient Population | Lead Investigator(s) in Cambridge |
| AZD1390 | ATM with RT | Glioblastoma | S Jeffries / G Doherty |
| Basket of Baskets | PD-L1 | Solid tumours with high mutational load/MSI | R Baird |
| CALIBRATION | ctDNA evaluation | Advanced oesophageal malignancies | S Pacey |
| GO40782 | NTRK1/2/3 | Proven NTRK1/2/3 gene rearrangements | S Pacey |
| LEAP-005 | PD-1 & RTK | Advanced TNBC, ovarian cancer, gastric cancer, GBM or BTC | B Basu |
| PATRIOT | ATR | Any tumour type – palliative radiotherapy combined with ATR inhibitor | R Baird |
| MOv18 igE | α-folate receptor | Gyane aFR+ | B Basu |
| Atrium | ATR | Solid tumours | D Jodrell |
| AZD9833 | ER | ER+ HER2- advanced breast cancer | R Baird |
| PARADIGM-2 | PARP | Glioblastoma | S Jefferies/ R Baird |
| AZD6738 | ATR inhibitor | Non-small cell lung cancer, Squamous cell head and neck cancers, module 3 will be open to all comers | D Jodrell |
| BT1718 | MT1-MMP | NSCLC, solid tumours with high MT1-MMP expression | B Basu |
| Incyte 86550-102 | Multiple | Advanced solid tumours | B Basu |
